We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...

Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...

Roivant is once again reaping the benefits of its bespoke business model. This time, it's selling Dermavant to Organon for up ...

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.